FEBRUARY 2026 Fourth Quarter & Full-Year 2025 Financial Results & Corporate Progress In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted ...

Core Viewpoint - XOMA Royalty Corporation announces the resignation of CFO Thomas Burns, who has been instrumental in the company's transition to a royalty aggregator, and appoints Jeffrey Trigilio as the new CFO to continue the company's growth strategy in the biotech sector [1][2]. Company Leadership Transition - Thomas Burns is stepping down after nearly two decades of service, with CEO Owen Hughes expressing gratitude for his contributions to the company's financial foundation and growth [2]. - Jeffrey Trigilio has been appointed as the new CFO, bringing extensive experience from various biotech companies and investment banks, including his recent role at Obsidian Therapeutics [2][3]. Strategic Direction - The leadership team, under Trigilio, aims to enhance the royalty portfolio through disciplined capital deployment, robust diligence, and innovative deal structuring to generate shareholder value [3]. - XOMA Royalty operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical companies, providing sellers with non-dilutive funding [3]. Portfolio Overview - XOMA Royalty's portfolio includes commercial assets such as VABYSMO, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY, and DSUVIA, with other assets being investigational compounds [6].

Core Insights - Day One Biopharmaceuticals is set to present new data on OJEMDA (tovorafenib) demonstrating durable responses and clinical stability in pediatric low-grade glioma (pLGG) patients at the Society for Neuro-Oncology (SNO) meeting [1][3] Company Overview - Day One Biopharmaceuticals focuses on developing targeted therapies for life-threatening diseases, particularly in pediatric cancer, addressing a critical unmet need in therapeutic development [11][12] - The company is based in Brisbane, California, and aims to redefine cancer drug development for all ages [11][12] Product Information - Tovorafenib (OJEMDA) is a Type II RAF kinase inhibitor approved for treating patients aged 6 months and older with relapsed or refractory pLGG harboring BRAF alterations [4][6] - The drug has received Breakthrough Therapy and Rare Pediatric Disease designations from the FDA, indicating its potential significance in treating pLGG [6] Clinical Trial Insights - The pivotal Phase 2 FIREFLY-1 trial evaluated tovorafenib in 137 patients, showing an overall response rate (ORR) of 67% and a median duration of response (DOR) of 16.6 months [8] - The trial results indicate sustained efficacy and long-term response in patients, reinforcing the clinical evidence for OJEMDA's differentiated profile [3][8] Pediatric Low-Grade Glioma Context - Pediatric low-grade glioma is the most common brain tumor in children, with significant incidence rates in the US and Europe, and BRAF alterations are present in over 50% of cases [9] - The condition often requires long-term treatment due to its chronic nature and the profound side effects associated with both the tumor and its treatment [9]

Financial Performance - Since launch, OJEMDA net product revenue reached $87.7 million[10, 14] - In Q1 2025, OJEMDA net product revenue was $30.5 million[10, 14, 19] - Q1 2025 saw a $3 million (+11%) increase in U S net product revenue compared to Q4 2024[14, 19] - Total revenue for Q1 2025 was $30.8 million[29] - The company holds a strong financial position with $473 million in cash[10, 29] - Net loss for the company was ($360) million[29] Commercial Performance - Cumulative prescriptions since launch totaled 2,571[14, 21] - Prescription growth in Q1 2025 was driven by new patient starts and continued therapy among on-label patients[21] Market Opportunity - Priority 1 centers manage approximately 4,000 estimated patients[24] - Priority 2 centers manage approximately 5,000 estimated patients[24] - Priority 3 centers manage approximately 4,000 estimated patients[24]

Core Viewpoint - XOMA Royalty Corporation has successfully sold its remaining Kinnate pipeline assets for up to $270 million in upfront and milestone payments, along with royalties on future commercial sales [1][2] Group 1: Financial Details - The total potential financial benefit from the sale includes up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens [1] - Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related payments made to XOMA Royalty prior to April 2, 2029 [2] Group 2: Company Background - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical or biotechnology companies [3] - The company provides non-dilutive, non-recourse funding to sellers, enabling them to advance their internal drug candidates or for general corporate purposes [3] Group 3: Current Portfolio - As of the date of the press release, XOMA Royalty's milestone and royalty portfolio includes commercial assets such as VABYSMO®, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY®, and DSUVIA® [6]